Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MOP.0000000000000252 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel inclusion in the silvery hair syndromes: unravelling the mystery behind the silvery hair of homocystinuria.
BMJ Case Rep
January 2025
Radiology, AIIMS Bibinagar, Hyderabad, India.
Homocystinuria is a disorder of methionine metabolism leading to abnormal accumulation of homocysteine and its metabolites in blood and urine. This condition presents with a wide range of cutaneous and systemic features. This case report focuses on the particular cutaneous finding of silvery hair in this patient and its examination under a microscope that reveals an unusual and not yet reported finding of melanin clumps.
View Article and Find Full Text PDFBaricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study.
J Dermatolog Treat
December 2025
Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Baricitinib, a JAK 1/2 inhibitor, is approved for treating severe alopecia areata (AA). This study aimed to evaluate the long-term effectiveness and safety of baricitinib in a real-world setting over 52 weeks. This multicenter retrospective study included 96 adult patients diagnosed with severe AA from 11 Italian Dermatology Units.
View Article and Find Full Text PDFA real-world study to assess the disease control of moderate to severe atopic dermatitis in patients receiving dupilumab therapy, with atopic dermatitis control tool in Gulf countries.
J Dermatolog Treat
December 2025
Sanofi-Evidence Generation and Dissemination Manager Greater Gulf, UAE.
Purpose/aim Of The Study: There is limited real-world evidence regarding the effectiveness and safety of dupilumab in Gulf countries. The study aimed to evaluate atopic dermatitis (AD) disease control in adult and adolescent patients (≥12 years) treated with dupilumab in Gulf countries.
Materials And Methods: This observational study included patients with moderate-to-severe AD who initiated dupilumab within 30 days.
Long-Term efficacy and safety analysis of secukinumab in the treatment of pediatric generalized pustular psoriasis: a real-world study.
J Dermatolog Treat
December 2025
Department of Dermatology, Children's Hospital Affiliated to Kunming Medical University, Kunming, China.
To evaluate the long-term efficacy and safety of secukinumab in pediatric patients with generalized pustular psoriasis (GPP). A retrospective study was conducted from July 2021 to July 2024, including 10 children with GPP. Patients were divided into two age groups: children aged 0-3 years received 75 mg of secukinumab, while those aged 3-12 years received 150 mg.
View Article and Find Full Text PDFDrug Extravasation in a Tertiary Referral Children Hospital: A Prospective Cohort Study.
Clin Pediatr (Phila)
January 2025
Pediatric Dermatology Division, Department of Pediatrics, Imam Hossein Children's Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
Extravasation injuries are prevalent in pediatric hospitals and often result in tissue damage and extended hospital stays. However, limited data exist regarding risk factors for extravasation in children. This study aimed to identify these risk factors in pediatric patients receiving intravenous (IV) therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!